Atossa Genetics Inc.
(NASDAQ : ATOS)

( )
ATOS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
MDTMedtronic PLC
0.87%92.690.6%$562.90m
ABTAbbott Laboratories
1.46%79.980.8%$459.35m
TMOThermo Fisher Scientific Inc.
0.96%266.051.0%$384.70m
ALGNAlign Technology, Inc.
2.19%259.296.3%$384.43m
ISRGIntuitive Surgical, Inc.
0.58%562.722.4%$326.98m
EWEdwards Lifesciences Corporation
-0.81%189.351.2%$293.81m
BSXBoston Scientific Corporation
0.53%38.171.1%$266.35m
SYKStryker Corporation
1.31%196.121.3%$229.80m
BDXBecton, Dickinson and Company
1.21%247.641.1%$228.82m
DXCMDexCom, Inc.
0.54%146.948.5%$219.04m
BAXBaxter International Inc.
0.85%77.601.7%$212.21m
TNDMTandem Diabetes Care, Inc.
0.90%71.954.1%$208.18m
WATWaters Corporation
0.50%246.493.5%$139.75m
ZBHZimmer Biomet Holdings, Inc.
0.33%125.731.7%$139.05m
ABMDABIOMED, Inc.
1.83%339.363.3%$131.99m

Company Profile

Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.